Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IP-001 as Adjuvant Therapy in Hepatocellular Carcinoma
NCT06526338Phase 2Recruiting
- Start
- Jul 2024
- Primary completion
- Dec 2029
- Modality
- Injectable Hydrogels, Implantable Hydrogels, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IP-001 in hepatocellular carcinoma (HCC). Started Jul 2024; status: recruiting.
02
Drugs
IP-001
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06526338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06526338.